244 related articles for article (PubMed ID: 11669508)
21. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
[TBL] [Abstract][Full Text] [Related]
22. The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
Stahl SM
J Clin Psychiatry; 2000 Oct; 61(10):710-1. PubMed ID: 11078030
[TBL] [Abstract][Full Text] [Related]
23. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Aguglia E; Onor ML; Saina M; Maso E
Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
[TBL] [Abstract][Full Text] [Related]
24. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis F
Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic treatment expectations in the management of dementia with Lewy bodies.
Kaufer DI
Dement Geriatr Cogn Disord; 2004; 17 Suppl 1():32-9. PubMed ID: 14676467
[TBL] [Abstract][Full Text] [Related]
26. [Do medicines with aim to anti-Alzheimer favor the arisen of epileptic crisis? Discussion about 3 clinical cases].
Roy M; Castro-Lionard K; Crawford-Achour E; Desseigne N; Beyens MN; Guy C; Imler D; Cornillon D
Therapie; 2011; 66(3):291-3. PubMed ID: 23189344
[No Abstract] [Full Text] [Related]
27. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
28. [Acetylcholinesterase inhibitors for dementia--an update].
Anghelescu I; Heuser I
MMW Fortschr Med; 2007 May; 149 Suppl 2():76-8. PubMed ID: 17724973
[TBL] [Abstract][Full Text] [Related]
29. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
[TBL] [Abstract][Full Text] [Related]
30. A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
Alisky JM
J Alzheimers Dis; 2003 Dec; 5(6):477-8. PubMed ID: 14757938
[No Abstract] [Full Text] [Related]
31. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.
Seltzer B
J Int Med Res; 2006; 34(4):339-47. PubMed ID: 16989488
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
33. [Galanthamine versus donepezil in the treatment of Alzheimer's disease].
López-Pousa S; Garre-Olmo J; Vilalta-Franch J
Rev Neurol; 2007 Jun 1-15; 44(11):677-84. PubMed ID: 17557224
[TBL] [Abstract][Full Text] [Related]
34. Cholinesterase inhibitors stabilize Alzheimer's disease.
Giacobini E
Ann N Y Acad Sci; 2000; 920():321-7. PubMed ID: 11193171
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacotherapy for Alzheimer's disease].
Verhey FR
Tijdschr Psychiatr; 2006; 48(1):17-26. PubMed ID: 16955982
[TBL] [Abstract][Full Text] [Related]
36. Evidence-based pharmacotherapy of Alzheimer's disease.
Evans JG; Wilcock G; Birks J
Int J Neuropsychopharmacol; 2004 Sep; 7(3):351-69. PubMed ID: 15228642
[TBL] [Abstract][Full Text] [Related]
37. Treatment of Alzheimer's disease in the long-term-care setting.
Smith DA
Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
[TBL] [Abstract][Full Text] [Related]
38. Effective pharmacological management of Alzheimer's disease.
Atri A
Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
[TBL] [Abstract][Full Text] [Related]
39. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Prasher VP
Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
[TBL] [Abstract][Full Text] [Related]
40. An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients.
Whyte EM; Lenze EJ; Butters M; Skidmore E; Koenig K; Dew MA; Penrod L; Mulsant BH; Pollock BG; Cabacungan L; Reynolds CF; Munin MC
Cerebrovasc Dis; 2008; 26(3):317-21. PubMed ID: 18667813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]